Scholarlink

Objective <p>Metastatic breast cancer is a disease with poor prognosis. For many years, it has been treated with endocrine therapy; however, due to the promising results of CDK 4/6 inhibitors, their combination with endocrine therapy has recently become an essential component of metastatic breast cancer treatment. Although no standardized approach exists for evaluating the response to CDK 4/6 inhibitors, assessment with 18&#xa0;F-FDG PET/CT may be possible. In this study, we aimed to assess the treatment response using 18&#xa0;F-FDG PET/CT SUVmax values in hormone receptor–positive metastatic breast cancer patients receiving CDK 4/6 inhibitors.</p> Methods <p>Our study was designed as a single-center, retrospective analysis including 94 patients (93 females, 1 male). The mean age at diagnosis was 55 years. The most commonly used treatment combination was ribociclib + letrozole (45.7%). Neutropenia was the most frequent adverse event associated with CDK 4/6 inhibitors (35.5% of patients), followed by fatigue (25.8%) and nausea (19.4%).</p> Results <p>The mean highest SUVmax value (primary tumor + metastases) before CDK4/6 inhibitor treatment was 11.20, which decreased to 7.32 after treatment initiation (<i>p</i> = 0.001). Patients with a marked absolute reduction in SUVmax (AUC: 0.769, <i>p</i> = 0.001, cut-off: 3.35) had longer progression-free survival (PFS) compared with those without a reduction (28.92 months vs. 14.47 months). The difference between pre- and post-treatment SUVmax values was significantly associated with both Clinical Benefit Rate (CBR) and Objective Response Rate (ORR) (<i>p</i> = 0.001).</p> Conclusion <p>Early changes in 18&#xa0;F-FDG PET/CT SUVmax values can serve as a valuable predictive marker for treatment response and survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of 18 F-FDG PET/CT SUVmax values in evaluating treatment response in hormone receptor–positive metastatic breast cancer patients receiving CDK4/6 inhibitor therapy

  • 期刊论文

  • 发表日期：

    2026年5月29日

查看全文
  • Rahime Dilara Özbek,
  • Aydın Aytekin,
  • Enes Yerdes,
  • Umut Elboga

摘要

Objective

Metastatic breast cancer is a disease with poor prognosis. For many years, it has been treated with endocrine therapy; however, due to the promising results of CDK 4/6 inhibitors, their combination with endocrine therapy has recently become an essential component of metastatic breast cancer treatment. Although no standardized approach exists for evaluating the response to CDK 4/6 inhibitors, assessment with 18 F-FDG PET/CT may be possible. In this study, we aimed to assess the treatment response using 18 F-FDG PET/CT SUVmax values in hormone receptor–positive metastatic breast cancer patients receiving CDK 4/6 inhibitors.

Methods

Our study was designed as a single-center, retrospective analysis including 94 patients (93 females, 1 male). The mean age at diagnosis was 55 years. The most commonly used treatment combination was ribociclib + letrozole (45.7%). Neutropenia was the most frequent adverse event associated with CDK 4/6 inhibitors (35.5% of patients), followed by fatigue (25.8%) and nausea (19.4%).

Results

The mean highest SUVmax value (primary tumor + metastases) before CDK4/6 inhibitor treatment was 11.20, which decreased to 7.32 after treatment initiation (p = 0.001). Patients with a marked absolute reduction in SUVmax (AUC: 0.769, p = 0.001, cut-off: 3.35) had longer progression-free survival (PFS) compared with those without a reduction (28.92 months vs. 14.47 months). The difference between pre- and post-treatment SUVmax values was significantly associated with both Clinical Benefit Rate (CBR) and Objective Response Rate (ORR) (p = 0.001).

Conclusion

Early changes in 18 F-FDG PET/CT SUVmax values can serve as a valuable predictive marker for treatment response and survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.